Unidad de Epidemiología y Evaluación, Instituto Universitario Fundación Parc Tauli, Universidad Autónoma de Barcelona, Sabadell (Barcelona), Spain.
Intensive Care Med. 2011 Mar;37(3):444-52. doi: 10.1007/s00134-010-2102-3. Epub 2010 Dec 9.
Severe sepsis is associated with high mortality and increased costs. The 'Surviving Sepsis Campaign' (SSC) protocol was developed as an international initiative to reduce mortality. However, its cost-effectiveness is unknown.
To determine the cost-effectiveness of the SSC protocol for the treatment of severe sepsis in Spain after the implementation of an educational program compared with the conventional care of severe sepsis.
Observational prospective before-and-after study.
59 medical-surgical intensive care units located throughout Spain.
A total of 854 patients were enrolled in the pre-educational program cohort (usual or standard care of severe sepsis) and 1,465 patients in the post-educational program cohort (SSC protocol care of severe sepsis).
The educational program aimed to increase adherence to the SSC protocol. The SSC protocol included pharmacological and medical interventions.
Clinical (hospital mortality) and economic (health-care resource and treatment costs) outcomes were recorded. A health-care system perspective was used for costs. The primary outcome was incremental cost-effectiveness ratio (ICER).
Patients in the SSC protocol care cohort had a lower risk of hospital mortality (44.0% vs. 39.7%, P = 0.04). However, mean costs per patient were 1,736 euros higher in the SSC protocol care cohort (95% CI 114-3,358 euros), largely as a result of increased length of stay. Mean life years gained (LYG) were higher in the SSC protocol care cohort: 0.54 years (95% CI 0.02-1.05 years). The adjusted ICER of the SSC protocol was 4,435 euros per LYG. Nearly all (96.5%) the bootstrap replications were below the threshold of 30,000 euros per LYG.
The SSC protocol seems to be a cost-effective option for treating severe sepsis in Spain.
严重脓毒症与高死亡率和增加的成本相关。“拯救脓毒症运动”(SSC)方案是作为一项国际倡议制定的,旨在降低死亡率。然而,其成本效益尚不清楚。
确定在西班牙实施教育计划后,与严重脓毒症常规治疗相比,SSC 方案治疗严重脓毒症的成本效益。
观察性前瞻性前后研究。
西班牙各地的 59 个内科-外科重症监护病房。
共有 854 名患者被纳入教育前计划队列(严重脓毒症的常规或标准治疗),1465 名患者被纳入教育后计划队列(严重脓毒症的 SSC 方案治疗)。
教育计划旨在提高对 SSC 方案的依从性。SSC 方案包括药物和医疗干预。
临床(住院死亡率)和经济(医疗资源和治疗费用)结果。采用医疗保健系统视角进行成本分析。主要结果是增量成本效益比(ICER)。
SSC 方案治疗组患者的住院死亡率风险较低(44.0%比 39.7%,P = 0.04)。然而,SSC 方案治疗组的每位患者的平均费用高出 1736 欧元(95%CI 114-3358 欧元),主要是由于住院时间延长所致。SSC 方案治疗组的平均生命年获益(LYG)更高:0.54 年(95%CI 0.02-1.05 年)。SSC 方案的调整 ICER 为 4435 欧元/LYG。近 96.5%的bootstrap 复制结果均低于 30000 欧元/LYG 的阈值。
SSC 方案似乎是西班牙治疗严重脓毒症的一种具有成本效益的选择。